Troponin T Elevation in Patient Undergoing Hip Fracture Surgery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01352754|
Recruitment Status : Unknown
Verified December 2013 by David Rott, Hadassah Medical Organization.
Recruitment status was: Active, not recruiting
First Posted : May 12, 2011
Last Update Posted : December 12, 2013
Background: Patients undergoing hip fracture surgery are elderly and usually have co-morbidities; hence they are at risk for perioperative MI. Troponin is the gold standard for diagnosis of myocardial damage and currently the cornerstone of MI diagnosis. Perioperative troponin elevation is a poor prognosis factor. The significance of minor troponin elevation, detected by highly sensitivity troponin T assay, is unknown.
Objectives: To determine the frequency of perioperative troponin T elevation using highly sensitivity troponin T assay, and to determine the clinical significance of this elevation.
Methods: Serum Troponin T levels of patients undergoing hip fracture surgery will be tested prior to surgery 48 hrs and 72 hrs after surgery, using highly sensitivity troponin T assay.
Patients will be followed for 1 year. Primary outcomes- The number of patients with elevated troponin levels perioperatively and cardiac mortality at 3 months, 6 months and 1 year.
|Condition or disease|
Background and Rational
Hip fractures are an important cause of morbidity and mortality in the elderly. Surgery (i.e. total hip fracture surgery or replacement) is associated with better outcome; however these elderly patients have other comorbidities which put them at risk for non surgical perioperative complications .
Peri-operative myocardial infarction (MI) is associated with increased mortality and morbidity . Peri-operative MI currently diagnosed by presence of either symptoms or ischemic ECG changes, together with an elevated troponin level as measured by conventional assay.
The new highly sensitive troponin T (HS Tn T) assay, permitting measurement of concentrations that are lower by a factor of 10 than those measurable with conventional assays .
The fundamental objective of our research is to further elucidate the magnitude and clinical relevance of minor perioperative TnT elevations.
Our specific objectives are:
A.To determine what is the frequency of HS Tn T elevation in patients undergoing hip fracture surgery.
B.To determine whether the presence of perioperative Tn T elevation using the HS assay is associated with higher mortality and morbidity.
Primary end points:
- The number of patients with elevated HS Tn T levels postoperatively.
- Cardiac mortality at 3 moths, 6 months and 1 year.
Secondary end points:
- Total mortality at 3 moths, 6 months and 1 year.
- Hospitalization for ACS and/or CHF at 3 months, 6 months and 1 year.
Patients admitted with traumatic femoral neck fracture will be recruited if surgery is planned.
Clinical evaluation for symptoms and signs of myocardial ischemia will be performed prior to surgery and 24 hrs after surgery.
Serum Tn T levels will be tested prior to surgery 48 hrs and 72 hrs after surgery, using HS Tn T assay.
ECG monitoring will be performed prior to surgery and 24 hrs after surgery. Patients will be followed for 1 year.
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Prognosis Significance of Troponin T Elevation as Detected by Highly Sensitive Assay in Patient Undergoing Hip Fracture Surgery|
|Study Start Date :||April 2011|
|Estimated Primary Completion Date :||February 2014|
|Estimated Study Completion Date :||March 2014|
- The number of patients with elevated HS Tn T levels post operatively. [ Time Frame: One year ]
- Cardiac mortality [ Time Frame: one year ]
- Total mortality [ Time Frame: One year ]
- Any hospitlization [ Time Frame: One year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01352754
|Hadassah hebrew university medical centers|
|Principal Investigator:||David Rott, MD||Hadassah-Hebrew University Hospital|